Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Jilin Province Huinan Changlong Bio-pharmacy Co Equity-to-Asset Related Terms
Jilin Province Huinan Changlong Bio-pharmacy Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co Equity-to-Asset Chart
Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jilin Province Huinan Changlong Bio-pharmacy Co Equity-to-Asset vs Drug Manufacturers Industry
Jilin Province Huinan Changlong Bio-pharmacy Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a Equity-to-Asset of 0.66 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. This is near median its historical median of 0.72. Over the past decade, Jilin Province Huinan Changlong Bio-pharmacy Co's Equity-to-Asset has ranged from 0.63 to 0.82. According to the industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #412 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's Equity-to-Asset too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current Equity-to-Asset of 0.66 is near median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 0.82. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 0.66 is 10% above this industry median. Based on the distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #412 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #412 out of 1006 companies for Equity-to-Asset. This puts Jilin Province Huinan Changlong Bio-pharmacy Co in the upper half of its industry. The industry median Equity-to-Asset is 0.60. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 0.66 is 10% above this benchmark. Historically, Jilin Province Huinan Changlong Bio-pharmacy Co's own Equity-to-Asset has ranged from 0.63 to 0.82 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.60, Jilin Province Huinan Changlong Bio-pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jilin Province Huinan Changlong Bio-pharmacy Co's current Equity-to-Asset of 0.66 is 10% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jilin Province Huinan Changlong Bio-pharmacy Co's current Equity-to-Asset is 0.66, which is near median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.20, compared to a current price of €0.25 — trading 25% above its estimated fair value. The current Equity-to-Asset is 0.66, which is near median its 10-year median of 0.72 and 10% above the Drug Manufacturers industry median of 0.60. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL), the current Equity-to-Asset is 0.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of €0.25 is trading 25% above its estimated GF Value™ of €0.20.
GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Modestly Overvalued.
Key valuation signals for FRA:JIL:
Equity-to-Asset: 0.66 (near median its 10-year median of 0.72)
GF Value™: €0.20 vs. price of €0.25 (25% above fair value)
Industry Position: 10% above the Drug Manufacturers median (#412 of 1006)
No single metric tells the full story. See the FRA:JIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
45GF Score
Get the complete analysis for FRA:JIL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JIL has been successfully added to your 
